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Abstract
Carcinoma are complex societies of mutually interacting cells in which there is a progressive failure of normal homeostatic
mechanisms, causing the parenchymal component to expand inappropriately and ultimately to disseminate to distant sites.
When a cancer cell metastasizes, it first will be exposed to cancer associated fibroblasts in the immediate tumor
microenvironment and then to normal fibroblasts as it traverses the underlying connective tissue towards the bloodstream.
The interaction of tumor cells with stromal fibroblasts influences tumor biology by mechanisms that are not yet fully
understood. Here, we report a role for normal stroma fibroblasts in the progression of invasive tumors to metastatic tumors.
Using a coculture system of human metastatic breast cancer cells (MCF10CA1a) and normal murine dermal fibroblasts, we
found that medium conditioned by cocultures of the two cell types (CoCM) increased migration and scattering of
MCF10CA1a cells in vitro, whereas medium conditioned by homotypic cultures had little effect. Transient treatment of
MCF10CA1a cells with CoCM in vitro accelerated tumor growth at orthotopic sites in vivo, and resulted in an expanded
pattern of metastatic engraftment. The effects of CoCM on MCF10CA1a cells were dependent on small amounts of active
TGF-b1 secreted by fibroblasts under the influence of the tumor cells, and required intact ALK5-, p38-, and JNK signaling in
the tumor cells. In conclusion, these results demonstrate that transient interactions between tumor cells and normal
fibroblasts can modify the acellular component of the local microenvironment such that it induces long-lasting increases in
tumorigenicity and alters the metastatic pattern of the cancer cells in vivo. TGF-b appears to be a key player in this process,
providing further rationale for the development of anti-cancer therapeutics that target the TGF-b pathway.
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Introduction
Carcinoma are complex societies of mutually interacting cells in
which there is a progressive failure of normal homeostatic
mechanisms, causing the parenchymal component to expand
inappropriately and ultimately to disseminate to distant sites. As
much as 50% or more of tumor bulk consists of non-parenchymal
cells often referred to as the tumor microenvironment, including
immune cells, cells of the microvasculature, and fibroblasts. Cells
of the tumor parenchyma and stroma engage in extensive cross-
talk, and the composition of the stroma and the nature of tumor
stromal interactions change over time with tumor progression
[1,2]. Tumor-stroma cross-talk influences tumor growth by
regulating angiogenesis, suppressing or subverting host immune
responses, modulating extracellular matrix, and secreting signaling
molecules which then in turn act on cells to further alter cell
physiology and to change the composition of the cellular and
acellular tumor microenvironment [2,3,4].
Fibroblasts are ubiquitous stromal cells which influence other
cells through the secretion of cytokines and growth factors [2,5,6].
The response of tumor parenchymal cells to fibroblasts depends on
many factors, including the nature and extent of the oncogenic
lesions in the tumor cells, and the age and activation state of the
fibroblasts [3,5,7,8,9].
While fibroblasts can have tumor suppressing activity the
phenotype of the fibroblast changes to a tumor promoting state as
carcinogenesis progresses [2]. This process occurs in two stages,
generating first reversibly ‘‘primed’’ and then irreversibly modified
fibroblasts with tumor-promoting properties [1]. Cancer-associated
fibroblasts (CAF) have properties distinct from normal fibroblasts and
actively promote tumorigenesis in mouse models of prostate and
breast cancer [3,10]. Typically CAFs have an activated phenotype,
expressing smooth muscle actin and showing increased motility [1].
CAFs secrete tumor promoting effectors such as SDF-1, HGF, and
TGF-b into the tumor microenvironment, and they overproduce
extracellular matrix, which contributes to tumor rigidity and an
altered signaling context thus further promoting tumor progression
[5,11,12]. Thus, the phenotype of local fibroblasts can persistently be
altered by complex reciprocal parenchymal-stromal interactions that
occur during cancer progression.
PLoS ONE | www.plosone.org 1 March 2010 | Volume 5 | Issue 3 | e9832TGF-bs are pleiotropic growth factors that play important roles
in maintaining normal tissue homeostasis [13]. Cells release latent
TGF-b into the microenvironment that upon activation binds to
specific serine-threonine kinase receptors. A heterodimeric recep-
tor complex consisting of the type II TGF-b receptor and the type
I TGF-b receptor (ALK5) then activates intracellular signaling
cascades that include the canonical Smad2/3 signaling path and
additional pathways such as TAK1-mediated p38- or JNK
signaling [14]. Dysregulation of TGF-b signaling has been
implicated in the carcinogenic process in many organs. In the
course of cancer progression, TGF-bs frequently switch from a
tumor suppressor to a tumor promoting role [14]. In the embryo,
expression of TGF-b is frequently seen at sites where critical
mesenchymal-epithelial interactions occur [15], suggesting that
TGF-bs may act as an important messenger between these two
compartments. In support of such a role, genetic loss of response to
TGF-b in fibroblasts is associated with aberrant expression of
growth factors and cytokines by the fibroblasts and results in the
development of premalignant and malignant lesions in several
overlying epithelia in stomach, prostate and breast [8,16,17].
However, forced overexpression of TGF-b primes fibroblasts to
promote the outgrowth of initiated human breast epithelial cells
[7]. These genetic approaches imply the existence of very
delicately balanced TGF-b-based homeostatic interactions be-
tween fibroblasts and the epithelial parenchyma.
When a cancer cell metastasizes, it first will be exposed to CAFs
in the immediate tumor microenvironment and then to normal
fibroblasts as it traverses the underlying connective tissue towards
the bloodstream. Here, we have asked whether the transient
interaction between tumor cells and normal fibroblasts can induce
phenotypic changes in the tumor cell that then affect its malignant
properties. We provide evidence that such an interaction induces
the secretion and/or activation of endogenous TGF-b by the
fibroblasts, which can enhance the malignant behavior of the
tumor cells in vivo.
Results
Medium Conditioned by Cocultures of Fibroblasts and
Tumor Cells Induces Cell Scattering in Tumor Cells
We investigated the crosstalk between human metastatic breast
cancer cells (MCF10CA1a hereafter referred to as CA1a) and
fibroblasts (DF) in a two-dimensional coculture system. Cocultures
of CA1a and DF formed an organized structure of tumor cell islets
that were surrounded by elongated fibroblasts (Fig. 1A) [18]. Using
CA1a cells and DF that were stably infected to report activation of
TGF-b signaling by expression of fluorescent protein, we found
that TGF-b signaling was activated in both tumor and stromal
cells in the cocultures, as compared to much lower levels of
activation in the homotypic cultures (Fig. 1A). This observation
suggested that cocultures might exhibit emergent properties that
were not present in the homotypic cultures. To address the effect
of coculturing on secreted components of the tumor microenvi-
ronment, we used conditioned media from 4 d old homotypic
cultures or cocultures to stimulate CA1a cells that had not been
previously exposed to any conditioned media. In scratch assays
medium conditioned by cocultures (CoCM) significantly acceler-
ated closure of the cell-cleared area as compared to medium
conditioned by tumor cells (TuCM), fibroblasts alone (FbCM), or
unconditioned control medium (medium) (Fig. 1B,C). A similar
result was seen when we treated tumor cells that had been plated
as a tight colony and assessed migration of cells out of the colony
(dot assay). This assay format more closely mimics the migration of
tumor cells out of a tumor into the surrounding environment, and
eliminates the wounding aspect of the scratch assay. In dot assays
CoCM caused scattering of tumor cells from the edges of the
colony, whereas colonies treated with homotypic media retained a
defined closed edge (Fig. 1B). While CoCM increased migration of
CA1a cells, proliferation of CA1a cells was unaffected by
treatment with CM (Fig. S1A). At the cellular level, CoCM
caused translocation of E-cadherin to the cytoplasm of CA1a cells
whereas E-cadherin remained localized at the cell membrane of
CA1a cells stimulated with TuCM or FbCM (Fig. 1B, D). Taken
together, these data suggest that coculture of tumor cells with
fibroblasts causes secretion of a soluble factor that increases cell
scattering and migration of tumor cells.
Cell Scattering Induced by Coculture Conditioned
Medium Depends on Active TGF-b Synthesized by
Fibroblasts
Cell scattering can be induced by a variety of cytokines and
growth factors [19,20,21,22,23,24,25,26], and so we tested the
effect of candidate factors in the dot assay. Only TGF-b (5 ng/ml,
Fig. 2A) but not other growth factors such as EGF (Fig. 2A, 25 ng/
ml to 250 ng/ml), TNF-a (1 ng/ml to 100 ng/ml), HGF (5 ng/ml
to 20 ng/ml), latency associated protein (LAP, 1 ng/ml to
100 ng/ml) or activin A (0.1 ng/ml to 10 ng/ml), induced
scattering of CA1a cells in dot assays. To address whether
endogenous TGF-b might be the factor in CoCM that induces
scattering, we used two different Smad-reporter systems to analyze
if CA1a cells respond to TGF-b in the CM and to sensitively
report on the presence of active TGF-b in the conditioned media.
CoCM induced higher Smad3- and Smad2-mediated luciferase
activity than did TuCM, FbCM, or medium, demonstrating that
CoCM derived TGF-b increases TGF-b signaling in tumor cells
(Fig. 2B). Furthermore, CoCM contained higher levels of active
TGF-b (194639 pg/ml) than the other conditioned media
(TuCM: 9466 pg/ml, FbCM: 106622 pg/ml, medium: 0 pg/
ml, Fig. 2C) as assessed by activation of a PAI-luciferase reporter
activity in CCL64 cells.
We next asked if TGF-b can induce scattering of CA1a cells
in concentrations similar to those secreted by cocultures into the
CoCM. To do this we stimulated CA1a with medium con-
taining 0.2 ng/ml TGF-b a n do b s e r v e dt h a tt h a tt h i sl o wl e v e l
of TGF-b was sufficient to induce tumor cell scattering (Fig. 2D).
Likewise, Smad3 driven GFP expression of the CAGA,GFP
reporter was increased by stimulation of CA1a cells with
0.2 ng/ml TGF-b (Fig. S2A). These results indicate that the
concentration of TGF-b that is secreted by cocultures into the
culture medium (CoCM) is sufficient to stimulate cell scattering
of CA1a cells.
To ask whether this effect was limited to CA1a cells or was more
universal we stimulated MCF-7 cells and T47D cells which form
adherent cell colonies in culture with 0.2 ng/ml TGF-b or CoCM.
Both, 0.2 ng/ml exogenous TGF-b and CoCM, were capable of
inducing scattering of MCF-7 and T47D cells (Fig. S3), indicating
that low concentrations of TGF-b as found in CoCM can increase
motility of several breast cancer cell lines.
Since tumor cells as well as fibroblasts can secrete TGF-b,w e
went on to identify the source of TGF-b in our coculture system.
While medium obtained from cocultures of CA1a cells with
embryonic fibroblasts derived from wild type mice stimulated
scattering of CA1a cells, coculture medium from CA1a cells with
embryonic fibroblasts derived from TGF-b1-null mice did not
induce scattering of CA1a cells (Fig. 2A). Taken together, these
data suggest that coculture of tumor cells with fibroblasts induces
production or activation of TGF-b1 by fibroblasts that then
stimulates scattering of the tumor cells.
Stromal TGF-b Aids Metastasis
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Signaling in CA1a Cells
The TGF-b signaling network includes canonical signaling via
Smad2/3 as well as non-canonical signaling cascades. Non-
canonical TGF-b signaling via MAPK pathways can be mediated
by TAK1 that then activates JNK- and p38-signaling (Fig. 3A)
[27,28,29]. Western blot analysis showed that Smad2, Smad3 and
TAK1 were phosphorylated to a greater extent by stimulation of
CA1a cells with CoCM than by stimulation with TuCM or FbCM
(Fig. 3A), indicating activation of both canonical and noncanonical
TGF-b signaling by CoCM. On a cellular level, CoCM induced
nuclear translocation of Smad2/3in CA1a cells as demonstrated
by immunostaining (Fig. 3B,C). This and the induction of Smad2
and Smad3 dependent luciferase activity (Fig. 2B) further
demonstrate that CoCM activates canonical TGF-b signaling in
CA1a cells. Similarly, immunofluorescence showed significantly
increased levels of proteins of the p38 signaling cascade (phospho-
p38, phospho-ATF-2, and phospho-MAPKAPK2) and of phos-
pho-JNK in CA1a cells stimulated with CoCM as compared to
CA1a cells stimulated with TuCM or FbCM (Fig. 4A,B). These
data demonstrate that canonical and non-canonical TGF-b
signaling cascades are activated upon stimulation of CA1a with
CoCM.
Figure 1. Cocultures of breast cancer cells are well organized and increase motility of tumor cells. A. Upper panel. Human breast cancer
cells (CA1a) and mouse dermal fibroblasts (DF) form a well organized 2D coculture where fibroblast streaks surround tumor cell islets. Middle panel.
Use of fibroblasts and CA1a cells that report Smad3 dependent TGF-b signaling by expression of RFP and GFP, respectively, demonstrates that TGF-b
signaling in both cell types is increased in cocultures as compared to the homotypic cultures. Bottom Panel. Outline of the tumor cell and fibroblast
compartments of the images shown in the middle panel. B. Medium conditioned by cocultures (CoCM) as compared to medium from homotypic
fibroblast (FbCM) and tumor cell (TuCM) cultures increases cell migration and cell scattering in scratch assays (24 h) and dot assays (4 d), and induces
cytoplasmic localization of E-cadherin as visualized by confocal microscopy (60 min). C. Influence of CoCM on closure of in vitro wounds (‘‘scratch
assay’’). Cells were plated to confluence, mitosis inhibited by preincubation with mitomycin, and cells then stimulated with conditioned media. CoCM
causes significantly faster closure of scratches as compared to all other conditioned media (scratch width after 24 h, n=8 samples/group, ANOVA/
Bonferroni; p,0.0001). D. Quantification of E-cadherin related immunofluorescence in CA1a cells treated with CM (Fig. 1B). Membranes and
cytoplasm of cells were gated separately and average signal intensity was determined using ImageJ. Ratios of membrane and cytoplasmic signal
were analyzed for statistical significance using GraphPad Prism (Kruskal-Wallis test/Dunn’s Multiple Comparison Test, p=0.0052).
doi:10.1371/journal.pone.0009832.g001
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increased levels of pSmad2, pTAK1, MKK3/6, pJNK, pp38,
pATF-2, and pMAPKAPK2 in Western blotting (Fig. S2B),
indicating that the TGF-b concentration that is found in CoCM
(0.2 ng/ml) can not only stimulate cell scattering (Fig. 2D), but also
is sufficient to activate canonical and non-canonical TGF-b
signaling cascades in CA1a cells.
We next asked if TGF-b signaling is necessary for CoCM
induced cell scattering and blocked ALK5, JNK, and p38
signaling during stimulation of CA1a with CoCM. The ALK5
inhibitor SB431542, the JNK inhibitor SP600125 and the p38
inhibitor SB203580 (Fig. 4B) all abolished tumor cell scattering
induced by CoCM. On a cellular level, those same inhibitors
reduced cytoplasmic translocation of E-cadherin induced by
Figure 2. TGF-b signaling induces scattering of CA1a cells. A. Exogenous TGF-b and fibroblast-released TGF-b induces cell scattering in dot
assays. Cells were plated into dot assays, incubated over night, and then stimulated with TGF-b (5 ng/ml), EGF (100 ng/ml), or vehicle (Control) for
4 d. Use of CoCM that was derived from cocultures of CA1a cells and TGFb1 knockout fibroblasts (CoCM(KO)) did not stimulate cell scattering while
conditioned medium from cocultures employing TGF-b1 wildtype fibroblasts (CoCM(WT)) did induce cell scattering. B. CoCM as compared to TuCM
and FbCM induces higher levels of CAGA (Smad3) and ARE (Smad2) mediated luciferase activity in CA1a cells (n=3, ANOVA/Dunnett’s Multiple
Comparison, p=0.0002 (ARE) and p,0.0001 (CAGA)). C. CoCM contains higher levels of TGF-b than TuCM and FbCM. CCL-64 cells were stimulated
with CM overnight and PAI-driven luciferase activity was measured. D. Scattering of CA1a cells is induced by addition of 0.2 ng/ml TGF-b to medium.
Cells were plated into dot assays, incubated overnight, and then stimulated with TGF-b (0.2 ng/ml) or vehicle for 4 d.
doi:10.1371/journal.pone.0009832.g002
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noncanonical TGF-b signaling cascades are involved in CoCM
induced cell scattering. Hence, CoCM stimulates tumor cell
scattering via activation of both canonical and noncanonical TGF-
b signaling.
CoCM Causes Increased Tumor Growth and Metastasis In
Vivo
Cell migration and cell scattering are in vitro correlates of
increased tumor cell malignancy. Thus, we next asked if the
transient in vitro exposure of CA1a cells to CoCM alters in vivo
tumorigenicity and metastatic potential of CA1a cells. First we
treated CA1a cells with CoCM for 4 d in vitro, and then we
washed, trypsinized, and injected cells into the mammary fat pads
of SCID mice (Fig. 5A). The ex vivo pretreatment of CA1a cells
with CoCM significantly accelerated primary tumor growth at the
orthotopic site when compared to CA1a cells treated with TuCM,
FbCM or medium alone (Fig. 5B).
The metastatic potential of CoCM treated cells was explored by
injection into the tail vein of NOD SCID mice because the CA1a
cell line does not metastasize efficiently from the orthotopic site.
Additionally this assay format allows metastatic efficiency to be
assessed independently of any effect of the experimental
intervention on tumor development at the primary site. Mice in
all experimental groups developed metastatic colonies of CA1a
cells in the lung (Fig. 5C) and no differences of the number of lung
colonies were found between the CoCM- and other treatment
groups at day 40 after injections of tumor cells (Fig. S4); however,
we observed a fairly high frequency of tumor colonization at
extrapulmonary sites exclusively in animals that were injected with
tumor cells that had been pre-treated with CoCM (Fig. 5C).
Extrapulmonary tumors were seen at subcutaneous sites in the
proximity of axillary and inguinal mammary fat pads, and in the
thoracic wall. Histologically, subcutaneous metastatic tumors
resembled the xenografted primary tumors (Fig. 6A, B).
We next asked if TGF-b was the component of the CoCM that
was responsible for the expanded metastatic range of CA1a cells
treated with CoCM. To do this we included the ALK5 kinase
inhibitor SB431542 during the 4 day pretreatment of CA1a cells
with CoCM. After washing away the SB431542 together with the
CoCM, the CA1a cells were injected into NOD SCID mice using
the same experimental design as before. Ex vivo incubation of
CA1a cells with CoCM and SB431542 as compared to CoCM,
resulted in significantly increased survival rates in tail vein
metastasis assays (Fig. 5D). Again, we observed that animals
injected with CoCM treated cells or with CoCM + SB435142
treated cells equally developed lung metastases (Fig. 5C), and
when re-plated in regular culture medium, proliferation of CA1a
cells pre-treated with CoCM was equal to proliferation of CA1a
cells pretreated with CoCM +SB431542, indicating that
SB431542 did not negatively influence proliferation or survival
of pre-treated cells (data not shown). However, only 1/14 animal
injected with CoCM + SB431542 developed an extrapulmonary
tumor, while 5/15 animals that were injected with CoCM treated
tumors developed extrapulmonary tumors in tail vein assays
(Fig. 5C). Thus, a transient in vitro exposure of CA1a cells to
CoCM and consequent activation of TGF-b signaling in these cells
not only durably increases tumorigenicity but also permits
successful colonization of a wider range of target tissues.
Active TGF-b Signaling Is Sustained in Tumors
Originating from CoCM Treated Cells
We next asked if TGF-b signaling in CA1a cells is durably
increased in vivo after stimulation of CA1a cells with TGF-b
containing CoCM in vitro. Nuclear pSmad2 levels were higher
in xenograft tumors or metastatic tumors originating from
CoCM treated cells than in xenograft tumors originating from
medium treated cells (Fig. 6B). Thus, increased TGF-b
signaling in CA1a cells by treatment with CoCM is sustained
in vivo, indicating that the transient exposure of CA1a cells to
elevated TGF-b levels causes a durable change in TGF-b
signaling activity.
TGF-b Signaling Is Increased at the Tumor - Stroma
Border of Tumors in Several Mouse Models
Next, we investigated whether TGF-b signaling is increased
when tumor cells invade the fibroblast-containing stroma
surrounding a primary tumor as would be predicted from our
observations. Immunostaining of pSmad2 in sections of mammary
tumors derived from different mouse breast cancer models (CA1a
xenograft tumors, syngeneic mouse mammary tumor (4T1), and
tumors from the C3(1)TAg transgenic model) revealed that
pSmad2 levels are higher in cells at the tumor stroma border,
and particularly in those cells invading the surrounding stroma, as
compared to tumor cells in the center of the tumor (Fig. 6C). Thus,
activation of pSmad2 naturally occurs when tumor cells invade the
surrounding stroma.
Taken together, our results imply that tumor cells, once they
traverse through the surrounding stroma, can subvert normal
fibroblasts to increase levels of active TGF-b in the microenvi-
ronment that then induces tumor cell migration, cell scattering,
and an expanded metastatic pattern, thereby boosting the
malignancy of tumor cells (Fig. 7).
Discussion
Interactions between tumor cells and the fibroblasts of the
tumor microenvironment are complex, reciprocal and stage-
dependent [30,31,32]. Here we have shown that transient
interactions of breast carcinoma cells with normal fibroblasts in
vitro can increase tumor cell malignancy and expand the
metastatic range of tumor cells in vivo by a TGF-b dependent
mechanism. Specifically, the interaction of human breast
carcinoma cells with normal murine fibroblasts induces aberrant
secretion of active TGF-b by the fibroblasts. This transient
exposure of tumor cells to fibroblast-derived TGF-b then
durably increases tumorigenesis even when the two cell types
are no longer interacting. Thus, tumor cells traversing through
Figure 3. CoCM activates Smad2/3-signaling and the MAPK signaling cascades p38 and JNK in CA1a cells suggesting activation of
canonical and noncanonical TGF-b signaling by CoCM derived TGF-b.A .TGF-b activates canonical signaling via Smad2/3 and non-canonical
signaling via TAK-1 relayed JNK- and p38 signaling cascades. CoCM stimulated both, phosphorylation of TAK1, and phosphorylation of Smad2/
Smad3. Cells were incubated with CoCM for 30 min (pTAK1) or 60 min (pSmad2, pSmad3). B. CoCM as compared to TuCM and FbCM induces nuclear
localization of Smad2/3 within 60 min, indicating activation of canonical Smad signaling upon stimulation with CoCM. C. Quantification of Smad2/3
mediated immunofluorescence in CM treated CA1a cells (Fig. 2B). Nuclei and cytoplasm of cells were gated separately and average signal intensity
was determined using ImageJ. Ratios of nuclear and cytoplasmic signal intensities were analyzed for statistical significance using GraphPad Prism
(ANOVA/Dunnett’s Multiple Comparison Test, p,0.0001, n=number of cells analyzed).
doi:10.1371/journal.pone.0009832.g003
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normal fibroblasts so as to get a boost in the metastatic process
(Fig. 7). This phenomenon has a number of interesting features
that are discussed below.
Emergent Properties and Reciprocity in the Co-Cultures
The interaction between tumor cells and normal fibroblasts can
generate emergent system properties that are not seen when the cells
are cultured separately. Our experimental design allowed us to focus
Figure 4. CoCM activates the MAPK signaling cascades p38 and JNK signaling in CA1a. A. Stimulation of CA1a cells with CoCM as
compared to FbCM and TuCM for 60 min increases levels of phospho-p38 (pp38), pATF-2, pMAPKAPK-2, and pJNK as visualized by fluorescence
microscopy, indicating that CoCM activates these non-canonical TGF-b signaling cascades. For quantification of pp38-, pATF-2-, pMAPKAPK2- and
pJNK mediated immunofluorescence cells were gated and average signal intensity was determined using ImageJ. Ratios of nuclear and cytoplasmic
signal intensities were analyzed for statistical significance using GraphPad Prism (Kruskal-Wallis test/Dunn’s Multiple Comparison Test, p,0.0001
[pp38], p,0.0001 [pATF-2], p,0.0001 [pMAPKAPK2], p,0.00001 [pJNK]). 30 to 40 cells were analyzed per group. B. Inhibitors were added to cultures
30 min prior to stimulating CA1a cells with CoCM for 60 min. E-cadherin was visualized by immunocytochemistry and confocal microscopy. Nuclei
were stained with DAPI. For quantification of E-cadherin mediated the cell membrane and the cytoplasm were gated for each cell and average signal
intensities were determined using ImageJ. Ratios of nuclear and cytoplasmic signal intensities were analyzed for statistical significance using
GraphPad Prism (ANOVA/Dunnetts’s Multiple Comparison Test, p,0.0001. n = number of cells analyzed in each group.
doi:10.1371/journal.pone.0009832.g004
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start to identify soluble mediators. We showed that co-culture of the
two cell types significantly increased the levels of fibroblast derived
active TGF-b in the extracellular environment, and that this TGF-b
subsequently enhanced migration of the tumor cells in vitro and
malignant behavior in vivo. It has been previously proposed that
tumor cells can induce a reversibly ‘‘primed state’’ in normal
fibroblasts, in which the fibroblasts can promote tumorigenesis even
though they do not have all the characteristics of the irreversibly
modified CAFs [1]. Our data suggest that such priming may involve
cancer cell-induced production of active TGF-b by the fibroblasts. It
is likely that TGF-b produced by these primed fibroblasts contributes
to the elevated TGF-b levels that are seen in the vicinity of many
advanced human tumors.
Co-cultures of fibroblasts and tumor cellsshowed increased TGF-b
signaling in both cell compartments, consistent with the presence of
activated TGF-b in the CoCM (Fig. 1A). We have previously shown
that TGF-b derived from the tumor cell compartment in this co-
culture model can induce MMP-9 secretion by fibroblasts in a Smad-,
ras- and PI3K dependent fashion [18]. In the present work, we
demonstrated that TGF-b derived from the fibroblast compartment
enhanced the migration of tumor cells through the activation of
Smad-, p38- and JNK-signaling cascades. Together the data suggest
that TGF-b-mediated signaling between the tumor cells and
Figure 5. CoCM increases tumorigenicity and expands the metastatic pattern of CA1a cells. A. Experimental design of orthotopic
implantation- and tail vein injection models. CA1a cells were pre-treated ex vitro with CM for 4 days, trypsinized, washed, and resuspended in DPBS.
Orthotopic Implantation Model.4 610
4 cells in 50 ml DPBS were bilaterally injected into the axillary mammary fat pads of female SCID mice (15 animals
or 30 tumor inoculation sites/group). Tumor size was assessed thrice weekly using calipers. Estimated tumor volumes were calculated by the formula
(S6S6L)60.52, where S and L are the short and long dimensions, respectively [41]. Tail Vein Injection Model.2 610
5 cells in 100 ml DPBS were injected
into the tail vein of female NOD SCID mice, and animals were monitored twice weekly for signs of metastasis. B. Ex vivo pre-treatment of CA1a cells
with CoCM accelerates growth of orthotopic xenograft tumors in vivo. The axillary mammary fat pads of female SCID mice were bilaterally inoculated
with CA1a cells that were pre-treated with CM (15 animals or 30 tumor inoculation sites/group). Tumor volumes at day 23 were analyzed using
GraphPad Prism 5.0. Kruskal Wallis test/Dunn’s multiple comparison; p,0.001; CoCM vs TuCM: ***, CoCM vs FbCM: **, CoCM vs medium: ***, TuCM vs
FbCM: N.S., TuCM vs medium: N.S., FbCM vs medium: N.S.. Representative of 2 independent experiments. C. Ex vivo pre-treatment of CA1a cells with
CoCM results in extrapulmonary metastases in tail vein injection assays. CA1a cells were incubated with conditioned media for 4 days and injected
into the tail vein of female NOD SCID mice. While all animals developed lung metastases, only animals injected with CoCM treated CA1a cells
developed extrapulmonary tumors. Extrapulmonary tumor growth was suppressed when TGF-b signaling was inhibited by the ALK 5 inhibitor
SB431542 during exposure of CA1a cells to CoCM. Animals receiving CoCM pre-treated cells had significantly higher occurrence of extrapulmonary
tumors than all other groups (Chi Square Test, tail vein injection #1: p=0.0002; tail vein injection #2: p=0.0085). D. Functional TGF-b signaling of
tumor cells is required for CoCM induced formation of extrapulmonary metastases. Blocking of ALK5 mediated TGF-b signaling by the ALK5-inhibitor
SB435142 during in vitro exposure of CA1a cells to CoCM inhibited metastases and significantly increased survival time of animals in vivo (median
survival: CoCM: 62 days (n=13 animals), SB431542: 96 days (n=14 animals), Kaplan Maier Analysis, p,0.0001).
doi:10.1371/journal.pone.0009832.g005
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cascades in each partner, and has different molecular outcomes in
each compartment. It is currently not clear how the two cell types can
selectively respond to the TGF-b produced by the other, but this
phenomenon conceivably might reflect differences in TGF-b
isoforms, and/or structure of the latent complexes made by each
cell type, as well as cell specific regulation of signal flux through the
TGF-b network within each cell type. However, since MMP-9 can
create a microenvironment more favorableto invasion and metastasis
through activation of growth factors, specifically TGF-b,a n d
destruction of extracellular matrix [33], the combined biological
outcome of the differing effects of TGF-b on each compartment is
likely to be a further enhancement of malignant behavior (Fig. 7).
Transient Tumor-Fibroblast Interactions Generate Small
Magnitude Molecular Effects That Induce Major Changes
in Outcome
Exposure of rat mammary tumor cells to exogenous TGF-b ex
vivo has previously been shown to promote metastatic efficiency in
vivo [34]. Here we have shown that transient interactions between
tumor cells and normal fibroblasts, such as might occur when
tumor cells traverse the surrounding tissue, can have a similar
effect. The amount of active TGF-b that was produced by the
coculture was very low, and the activation of downstream signaling
pathways was similarly mild (Figs 2 to 5). Nevertheless, these small
magnitude, endogenous molecular effects altered the phenotype of
the tumor cell such that it showed significantly increased
malignant behavior even when no longer in contact with the
fibroblast compartment. The data imply that carcinoma cells that
have breached the basement membrane and are migrating
through underlying connective tissue may be able to subvert and
use resident, TGF-b secreting fibroblasts to boost their motility
and subsequent metastatic spread.
Underlying Mechanisms
TGF-b has a number of tumor cell-targeted effects that could
contribute to the enhanced malignancy, including enhancement of
tumor cell migration and invasion, direct effects on tumor cell
Figure 6. CoCM expands the metastatic pattern of CA1a cells and induces sustained TGF-b signaling via pSmad2. A. Extrapulmonary
tumors formed by CoCM pre-treated CA1a cells after tail vein injection were highly invasive. Extrapulmonary tumors were observed in the
subcutaneously, often in the proximity to mammary fat pads (arrows indicate a normal mammary duct, hematoxylin-eosin staining). B. Xenograft
tumors and extrapulmonary metastatic tumors derived from CoCM pre-treated cells have higher levels of nuclear pSmad2 than xenograft tumors
derived from medium pre-treated CA1a cells as shown by immunostaining. Levels of pSmad2 in xenograft and metastatic tumors were higher in
CA1a cells invading the surrounding tissue (arrows) as compared to tumor cells in the center of tumors. The negative control was obtained by
omitting the primary antibody. C. Nuclear pSmad2 is increased in tumor cells at the tumor stroma border (arrows) as compared to cells in the center
of tumors that spontaneously developed in a C3(1)TAg model of breast cancer and in an orthotopic syngeneic model of breast cancer (4T1 cells/
BALB/c mice).
doi:10.1371/journal.pone.0009832.g006
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and extracellular matrix components [14,35]. The stimulatory
effect of CoCM on primary tumor growth may reflect pro-survival
effects of TGF-b on CA1a cells as TGF-b reduces apoptosis of
CA1a cells (Fig. S1B), possibly acting in concert with other as yet
unidentified trophic factors in the CM.
The ability of TGF-b to promote migration and invasion of
CA1a cells may contribute to the enhanced metastasis, but
additional mechanisms such as altered expression levels of
junctional proteins like E-cadherin, integrins, or chemokines and
chemokine receptors are also likely to play a role [36]. For
example, the organ tropism of metastatic tumors is determined in
part by the spectrum of chemokines and chemokine receptors that
they express [37], and TGF-bs have been shown to modulate
relevant chemokine ligand/receptor axes in other models. TGF-b
derived from cancer-associated fibroblasts upregulates CXCR4 in
initiated prostatic epithelial cells [38], and expression of CXCR4
correlates with lymph node metastasis in multiple human tumors
[39]. It will be the aim of future work to determine which
mechanism is relevant for the expanded metastatic range shown
by the CA1a breast cancer cells stimulated with fibroblast derived
TGF-b.
Consequences and Conclusions
In conclusion, our results demonstrate that a relatively short-
lived interaction between tumor cells and normal fibroblasts
induces changes in the localized extracellular microenvironment
that then substantially increase the malignancy of the tumor cells
even after the original interaction has ceased. The data imply that
normal resident fibroblasts that are exposed to direct contact with
invading tumor cells may boost the motility and subsequent
metastatic spread of these carcinoma cells. TGF-b appears to be a
Figure 7. Tumor-stroma interactions increase malignancy of tumor cells by bidirectional effects of TGF-b. Direct interactions of tumor
cells and fibroblasts as they occur when parenchymal tumor cells invade the underlying stroma increase secretion of TGF-b by tumor cells as well as
by fibroblasts. TGF-b has bidirectional effects on both cells types. Fibroblast derived TGF-b can directly stimulate tumor cell migration and
malignancy. Tumor cell derived TGF-b induces fibroblasts to secrete MMP-9 [18]. Increased MMP-9 levels then might further increase levels of active
TGF-b, and also facilitate matrix degradation and migration of tumor cells, further increasing the malignant potential of tumor cells.
doi:10.1371/journal.pone.0009832.g007
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development of anti-cancer therapeutics that target the TGF-b
pathway [40].
Materials and Methods
Cell Culture and Generation of Conditioned Media
MCF10CA1a (‘‘CA1a’’) is a malignant, metastatic human
breast cancer line [41]. Mouse dermal fibroblasts (DF) were
derived from newborn mice as previously described [42]. Mouse
embryonic fibroblasts were derived from embryos (ED 12 to ED
14) by suspending embryonic tissue in DMEM (Invitrogen,
Carlsbad, CA) supplemented with 10% fetal calf serum (‘‘fibro-
blast medium’’). CA1a and DF were respectively grown in
DMEM/F12 supplemented with 5% horse serum (‘‘CA1a
medium’’) and DMEM, low glucose (Invitrogen, Carlsbad, CA),
supplemented with 10% fetal bovine serum (Invitrogen or Gemini
Bio-Products, Woodland, CA) [18]. To obtain conditioned media
from homotypic cultures or cocultures, 1.5610
6 cells of each type
were plated in a 150 cm
2 dish and incubated in a 1:1 mixture of
CA1a- and fibroblast medium (‘‘coculture medium’’). Culture
supernatants were collected after 4 d and cells were removed by
centrifugation (200 g, 5 min). Acellular supernatants were diluted
with fresh coculture medium (conditioned medium, CM) and used
for further experiments [18].
Cell Scattering and Migration
Dot Assay. To assess cell scattering, 20 ml of cell suspension
(3610
6 CA1a cells/ml) were placed in each well of 6-well plates
and allowed to adhere to form tight well-circumscribed colonies.
After 3 hours non-attached cells were removed by rinsing the plate
with calcium-containing Dulbecco’s phosphate buffered saline
(DPBS, Invitrogen, Carlsbad, CA). Cells were incubated in regular
culture medium overnight, and then switched for 4 days to a 1:1
mixture of CM and fresh coculture medium. Cell scattering was
evaluated macroscopically and microscopically following staining
with hematoxylin-eosin. Unconditioned medium served as an
additional negative control. The effect of growth factors and
cytokines on cell scattering was assessed by adding the following
growth factors in concentrations as indicated to the culture
medium for 4 days: human TGF-b1, human EGF, LAP (all R&D
Systems, Minneapolis, MN), human TNF-a (PeproTech, Rocky
Hill, NJ), and HGF (kind gift from Don Bottaro). Where indicated,
small molecule inhibitors of various signaling pathways (ALK4,5,7:
SB431542, 5 mM, Sigma, St. Louis, MO; MEK/Erk: PD98059,
25 mM; p38: SB203580, 10 mM; JNK: SP600125, 10 mM (all
Calbiochem, San Diego, CA)) were added to cultures 30 min
before stimulation with the conditioned medium. Equal amounts
of DMSO served as a negative control.
Scratch Assay. CA1a cells were plated in 24-well plates and
grown to confluence. Cell proliferation was blocked by a 30 min
pretreatment with mitomycin C (25 mg/ml). A scratch was then
made in each well using a 100 ml pipette tip and cells were
stimulated with the various CM in 1:1 mixtures with fresh
coculture medium. The scratch width at different time points was
imaged and measured using ImagePro. Data were analyzed using
GraphPad Prism 2.0.
Immunostaining and Western Blotting
Immunofluorescence and Western Blotting were performed
following established protocols [18,43]. The following antibodies
were used: Immunofluorescence: phospho-JNK, phospho-p38,
phospho-ATF2, phospho-MAPKAPK2 (all 1:100, Cell Signaling,
Danvers, MA) and E-cadherin (1:800, Zymed, Carlsbad, CA).
Western Blotting: Smad3 (1:1000, Zymed), Smad2/3 (1:1000, BD
Biosciences, San Jose, CA), phospho-Smad3 (1:12 000, Gift from
E. Leoff), phospho-Smad2, phospho-TAK, TAK (both 1:1000,
Cell Signaling), and actin (1:60 000, BD Biosciences) for Western
Blotting. Immunoperoxidase staining [42] for phospho-Smad2
(1:500, Millipore, Temecula,CA) was performed on formalin-
fixed, paraffin-embedded tumor sections.
Transfection, Reporter Assays, and Lentiviral Infection
Transfection of CA1a cells with the CAGA12-luciferase plasmid
or with the reporter plasmids ARE-luciferase/FAST-1, and
lentiviral infections were performed as described previously [44,45].
Quantification of TGF-b
Levels of active TGF-b in CM were determined using PAI-
driven luciferase expression in CCL-64 cells [46]. Briefly, CCL-64
cells that were stably transfected with PAI-luc were cultured in 48-
well plates (20000 cells/well) in 200 ml RPMI supplemented with
5% FCS for 36 hours and serum starved (RPMI supplemented
with 1% FCS) for 8 hours. Then 100 ml medium was removed and
replaced with 100 ul CM (sample) or 100 ml unconditioned
medium spiked with varying concentrations of TGF-b1t o
establish a standard curve. Cells were incubated over night, and
luciferase assays were performed according to the manufacturer’s
instructions (Promega, Madison, WI).
In vivo Tumorigenesis
Female SCID and NOD SCID animals (age: 8–10 weeks) were
purchased from the NCI Animal Production Program. For
tumorigenesis studies, 4610
4 tumor cells in 50 ml DPBS were
bilaterally injected into the # II and # VII mammary fat pads of
female SCID mice. Tumor size was assessed using calipers. Tumor
volumes were calculated by the formula for an oblique spheroid
(S6S6L)60.52, where S and L are the short and long dimensions,
respectively. Tail vein injection assays were performed by injecting
2610
5 cells in 100 ml DPBS into the tail vein of female NOD
SCID animals [41]. Mice were euthanized after 8 weeks or when
animals became moribund and examined grossly on necropsy for
the presence of metastases in multiple organs. Metastasis was
confirmed histologically.
Orthotopic syngeneic mammary tumors of mouse breast cancer
cells (4T1) in BALB/c mice and C3(1)TAg tumors were grown as
previously described [47,48].
Statistical Analysis
Cumulative tumor volumes [47] and survival graphs were
analyzed by ANOVA (post hoc test Dunnett’s Multiple Compar-
ison Analysis), Kruskal-Wallis test (post hoc test Dunn’s Multiple
Comparison Analysis), Chi Square test, and Kaplan-Maier assays
using Graph Pad Prism 5.0b. Data are presented as mean 6
standard error of mean (SEM).
Supporting Information
Figure S1 Influence of conditioned media and TGF-beta on cell
proliferation and apoptosis. CA1a cells (2000/well) were plated
into 96 well plates and allowed to attach. Cell were then stimulated
with conditioned media or with TGF-beta (5 ng/ml) and
incubated at 37C, 5% CO2 for another 48 h. Thymidine
incorporation was performed as described earlier. BrdU incorpo-
ration and apoptosis were measured using the Cell Proliferation
(BrdU) kit and the Cell Death Detection kit (both Roche)
according to the manufacturer’s instructions.
Found at: doi:10.1371/journal.pone.0009832.s001 (0.17 MB TIF)
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non-canonical MAPK-signaling in CA1a cells. A. CA1a cells were
stably infected with CAGA12,GFP. Cells were serum starved
overnight and then stimulated with TGF-b in the concentrations
indicated. Images of confluent cultures were takes 24 h later and
green fluorescence analyzed using Image J. Data points present
mean + standard error of mean (SEM) of 9 field. B, C. Western
blot analysis demonstrates that TGF-b (0.2 ng/ml) activates
canonical and non-canonical TGF-b signaling as evident by
increased levels of pSmad2, pTAK412, pMKK3/6, pJNK, pp38,
pATF-2, and pMAPKAPK2; actin was used as loading control. C.
Quantification of data shown in B. Densitometry of bands was
performed using ImageJ, and data were analyzed in Excel.
Found at: doi:10.1371/journal.pone.0009832.s002 (0.26 MB TIF)
Figure S3 Scattering of the human breast cancer cells (MCF-7
and T47D) is induced by TGF-b (0.2 ng/ml) and CoCM. MCF-7
and T47D were cultured in DMEM supplemented with 10% FCS.
For experiments, cells were plated into 6-well plates, incubated
overnight, and then stimulated with TGF-b (0.2 ng/ml) or CM for
4 days. Colonies were visualized by H&E staining. well plates,
incubated overnight, and then stimulated with TGF-b (0.2 ng/ml)
or CM for 4 days. Colonies were visualized by H&E staining
Found at: doi:10.1371/journal.pone.0009832.s003 (0.51 MB TIF)
Figure S4 Pre-treatment of CA1a with CoCM does not
significantly alter lung metastases. CA1a cells were pre-treated
ex vitro with CM for 4 days, trypsinized, washed, and resuspended
in DPBS. 26105 cells in 100 ml DPBS were injected into the tail
vein of female NOD SCID mice, and animals were monitored
twice weekly for signs of metastasis. Animals were euthanized 40 d
after injection of tumor cells to assess lung metastases. Lungs were
fixed in 4% normal buffered paraformaldheyde. Tumor colonies
were counted in cross sections of the lung (1 section/lung). Data
were analyzed using GraphPad Prism (ANOVA/Dunnett Multi-
ple comparison test). Single data points and median with
interquartile range.
Found at: doi:10.1371/journal.pone.0009832.s004 (0.17 MB TIF)
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